Crinetics Pharmaceuticals (CRNX) Announces Earnings Results

Crinetics Pharmaceuticals (NASDAQ:CRNX) posted its quarterly earnings data on Monday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04, Fidelity Earnings reports. The company had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.25 million. Crinetics Pharmaceuticals had a negative return on equity of 30.41% and a negative net margin of 1,303.31%.

CRNX stock opened at $25.39 on Wednesday. The firm has a market cap of $607.38 million and a PE ratio of -11.39. Crinetics Pharmaceuticals has a twelve month low of $19.23 and a twelve month high of $42.00.

CRNX has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Crinetics Pharmaceuticals in a research note on Thursday, February 14th. They issued a “buy” rating and a $35.00 price objective on the stock. Cantor Fitzgerald initiated coverage on Crinetics Pharmaceuticals in a research note on Monday, March 11th. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, Zacks Investment Research lowered Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $37.20.

In other news, major shareholder Ventures Iv L.P. 5Am sold 154,839 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $24.25, for a total transaction of $3,754,845.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $22.25, for a total value of $9,278,250.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Crinetics Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) by 25.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 75,653 shares of the company’s stock after acquiring an additional 15,538 shares during the quarter. Geode Capital Management LLC owned approximately 0.31% of Crinetics Pharmaceuticals worth $2,268,000 at the end of the most recent reporting period. Institutional investors own 69.19% of the company’s stock.

WARNING: “Crinetics Pharmaceuticals (CRNX) Announces Earnings Results” was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.wkrb13.com/2019/05/15/crinetics-pharmaceuticals-crnx-announces-earnings-results.html.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Featured Story: How to Invest in Growth Stocks

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.